Konstantinos Dimitropoulos
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Konstantinos Dimitropoulos has a total of 111 co-authors. Here are the top co-authors by number of shared publications:
Vassilios Tzortzis
Department of Urology, Faculty of Medicine, School of Health Sciences, University Hospital of Larissa, University of Thessaly, Larissa, Greece
5 shared publications- Anastasios Karatzas
Department of Urology, University of Thessaly School of Medicine, Larissa, Greece
3 shared publications Michael Melekos
3 shared publications- Muhammad Imran Omar
Academic Urology Unit, University of Aberdeen, Aberdeen, UK
3 shared publications - Stavros Gravas
Medical School, University of Cyprus, Nicosia, Cyprus
3 shared publications Anastasios Karatzas
Department of Urology, Faculty of Medicine, School of Health Sciences, University Hospital of Larissa, University of Thessaly, Larissa, Greece
2 shared publications
Latest Publications
- Open Access
Post-Chemotherapy Retroperitoneal Lymph Node Dissection for Metastatic Testicular Cancer at a National Referral Centre
Objective: To assess the safety of open PC-RPLND at a high-volume national referral centre over the course of several years. Materials and Methods: A retrospective chart review of patients with testicular germ cell tumours (TGCTs) who underwent PC-RPLND at our institution between 2008 and 2023 was conducted. Patient demographics, clinical characteristics, intraoperative and postoperative parameters and adjunctive procedures were recorded. ClassIntra and Clavien Dindo classifications were used to assess intraoperative and postoperative complications, respectively. Results: In total, 165 patients were studied. The median (Q1–Q3) age of patients was 30.5 years (24.75–38.25), and the median maximum diameter of retroperitoneal masses was 50 mm (26.75–81.25). The most common adjunctive procedure was synchronous nephrectomy (n = 18, 11%) followed by vascular procedures (n = 7, 4.3%), ureteric reconstruction (n = 7, 4.3%), and partial hepatectomy (n = 3, 1.9%). Intraoperatively, 20, 8 and 1 patient had a grade I, II or V complication, respectively, according to the ClassIntra classification. The median estimated blood loss was 300 mL (120–740), the median duration of the procedure was 4.9 h (4–6 h) and the median length of stay was 8 days (7–10 days). Histopathological examination of the resected specimen showed teratoma in 51.9% of patients, followed by fibrosis/necrosis in 39.5%. A total of 40 patients (24.7%) experienced at least one complication. Conclusions: PC-RPLND is a complex operation, often accompanied by adjunctive surgical procedures and therefore must be conducted in high-volume referral centres to ensure safety and minimise complications.
Open AccessPost-Chemotherapy Retroperitoneal Lymph Node Dissection for Metastatic Testicular Cancer at a National Referral Centre
Objective: To assess the safety of open PC-RPLND at a high-volume national referral centre over the course of several years. Materials and Methods: A retrospective chart review of patients with testicular germ cell tumours (TGCTs) who underwent PC-RPLND at our institution between 2008 and 2023 was conducted. Patient demographics, clinical characteristics, intraoperative and postoperative parameters and adjunctive procedures were recorded. ClassIntra and Clavien Dindo classifications were used to assess intraoperative and postoperative complications, respectively. Results: In total, 165 patients were studied. The median (Q1–Q3) age of patients was 30.5 years (24.75–38.25), and the median maximum diameter of retroperitoneal masses was 50 mm (26.75–81.25). The most common adjunctive procedure was synchronous nephrectomy (n = 18, 11%) followed by vascular procedures (n = 7, 4.3%), ureteric reconstruction (n = 7, 4.3%), and partial hepatectomy (n = 3, 1.9%). Intraoperatively, 20, 8 and 1 patient had a grade I, II or V complication, respectively, according to the ClassIntra classification. The median estimated blood loss was 300 mL (120–740), the median duration of the procedure was 4.9 h (4–6 h) and the median length of stay was 8 days (7–10 days). Histopathological examination of the resected specimen showed teratoma in 51.9% of patients, followed by fibrosis/necrosis in 39.5%. A total of 40 patients (24.7%) experienced at least one complication. Conclusions: PC-RPLND is a complex operation, often accompanied by adjunctive surgical procedures and therefore must be conducted in high-volume referral centres to ensure safety and minimise complications.
- 1 December 2023
- Published by Bentham Science Publishers Ltd. in Current Cancer Drug Targets
- Vol. 23 (11) , 910-916
The Impact of Enhanced Recovery after Surgery Protocol Implementation on Postoperative Pain Management in the Era of Opioid Crisis: The Postchemotherapy Open RPLND Experience
Aim: Enhanced Recovery After Surgery (ERAS) protocols have been proven to optimize postoperative outcomes; however, misuse of opioid analgesics can still hinder postoperative recovery due to related side effects and potential complications. Introduction: To determine if the implementation of ERAS protocol in post-chemotherapy retroperitoneal lymph node dissection (PC-RPLND) patients could help with reducing postoperative pain and opioid use. Methods: A case-control study of consecutive testicular cancer patients with indications for PCRLPND, who were offered Conventional Post-operative Management (CPM) or ERAS protocol. Outcomes of interest included Visual Analogue Scale (VAS)-assessed pain level at postoperative days 3, 7, and 30, and Morphine-Equivalent Doses (MEDs)/postoperative day. Intraoperative parameters and postoperative complications were recorded. Parametric and non-parametric tests were used for statistical analysis. Results and Discussion: In total, 100 opioid-naïve PC-RPLND patients were studied. CPM and ERAS groups (36 and 64 patients, respectively) had similar demographic and baseline clinical characteristics). ERAS group patients had significantly lower blood loss (p=0.005), blood transfusion rate (p<0.001), and duration of the procedure (p<0.001). Post-operative complications were comparable between groups. Nausea and bowel disorders were numerically but not statistically more frequent in the CPM group. ERAS patients had shorter mean hospital stay (5.3±1.4 vs 7.4±1.6 days, p<0.001), lower daily MEDs (4.73±2.63 vs 7.04±2.29, p<0.001), and lower VAS scores on post-operative day 7 (3.89±1.07 vs 4.67±1.17, p=0.001). Post-operative pain was similar between groups on post-operative days 3 and 30. Conclusion: Systematic implementation of ERAS protocol after PC-RPLND improves pain management, optimizes patient recovery, and prevents over-prescription of opioid analgesics.
- 1 December 2023
- Published by Bentham Science Publishers Ltd. in Current Cancer Drug Targets
- Vol. 23 (11) , 910-916
The Impact of Enhanced Recovery after Surgery Protocol Implementation on Postoperative Pain Management in the Era of Opioid Crisis: The Postchemotherapy Open RPLND Experience
Aim: Enhanced Recovery After Surgery (ERAS) protocols have been proven to optimize postoperative outcomes; however, misuse of opioid analgesics can still hinder postoperative recovery due to related side effects and potential complications. Introduction: To determine if the implementation of ERAS protocol in post-chemotherapy retroperitoneal lymph node dissection (PC-RPLND) patients could help with reducing postoperative pain and opioid use. Methods: A case-control study of consecutive testicular cancer patients with indications for PCRLPND, who were offered Conventional Post-operative Management (CPM) or ERAS protocol. Outcomes of interest included Visual Analogue Scale (VAS)-assessed pain level at postoperative days 3, 7, and 30, and Morphine-Equivalent Doses (MEDs)/postoperative day. Intraoperative parameters and postoperative complications were recorded. Parametric and non-parametric tests were used for statistical analysis. Results and Discussion: In total, 100 opioid-naïve PC-RPLND patients were studied. CPM and ERAS groups (36 and 64 patients, respectively) had similar demographic and baseline clinical characteristics). ERAS group patients had significantly lower blood loss (p=0.005), blood transfusion rate (p<0.001), and duration of the procedure (p<0.001). Post-operative complications were comparable between groups. Nausea and bowel disorders were numerically but not statistically more frequent in the CPM group. ERAS patients had shorter mean hospital stay (5.3±1.4 vs 7.4±1.6 days, p<0.001), lower daily MEDs (4.73±2.63 vs 7.04±2.29, p<0.001), and lower VAS scores on post-operative day 7 (3.89±1.07 vs 4.67±1.17, p=0.001). Post-operative pain was similar between groups on post-operative days 3 and 30. Conclusion: Systematic implementation of ERAS protocol after PC-RPLND improves pain management, optimizes patient recovery, and prevents over-prescription of opioid analgesics.
- Open Access
- 5 September 2022
- Published by Springer Nature in World Journal of Urology
- Vol. 40 (10) , 2467-2472
The impact of low-pressure pneumoperitoneum on robotic-assisted radical cystectomy and intracorporeal ileal conduit urinary diversion: a case–control study
Purpose: To evaluate the role of low intra-abdominal pressure (IAP) in improving postoperative recovery in Robotic-assisted radical cystectomy (RARC) and intracorporeal ileal conduit urinary diversion (ICUD). Methods: A retrospective case–control study of 49 bladder cancer patients offered RARC/ICUD with standard (12 mmHg, n = 24) or low IAP (8 mmHg, n = 25). Outcomes of interest included length of procedure (LoP), estimated blood loss (EBL), blood transfusion, margin positivity rates, time to first flatus (TtFF), time to first bowel movement (TtFBM), ileus and small bowel obstruction (SBO) rates, time to safe discharge (TtSD), postoperative hospital stay (PHS) and pain levels on a postoperative day (POD) 1 and 3. Perioperative complications were recorded using the Clavien-Dindo system. Results: Demographic and baseline clinical characteristics, LoP, EBL and margin positivity rates were similar between groups. No transfusions were recorded. Median (IQR) TtFF, TtFBM and TtSD were significantly longer in Group 1 vs Group 2 (4 (1) vs 2 (1), 7 (3) vs 6 (2) and 8.5 (5.75) vs 5.0 (1), respectively). PHS and rates of postoperative ileus and SBO were lower in Group 2, however not statistically significant. Severe pain was uncommon in both groups but moderate/severe pain was significantly higher in Group 1 (95.8% vs 48% on POD1 and 62.5% vs 16% on POD3). No significant intraoperative complications were recorded and ≥ Grade 3 postoperative complications at 30 and 90 days were similar. Conclusion: With limitations, Low-IAP RARC can be safely offered to RARC/ICUD patients and leads to faster bowel recovery, and shorter time to safe discharge compared to standard pneumoperitoneum.
- 5 September 2022
- Published by Springer Nature in World Journal of Urology
- Vol. 40 (10) , 2467-2472
Open AccessThe impact of low-pressure pneumoperitoneum on robotic-assisted radical cystectomy and intracorporeal ileal conduit urinary diversion: a case–control study
Purpose: To evaluate the role of low intra-abdominal pressure (IAP) in improving postoperative recovery in Robotic-assisted radical cystectomy (RARC) and intracorporeal ileal conduit urinary diversion (ICUD). Methods: A retrospective case–control study of 49 bladder cancer patients offered RARC/ICUD with standard (12 mmHg, n = 24) or low IAP (8 mmHg, n = 25). Outcomes of interest included length of procedure (LoP), estimated blood loss (EBL), blood transfusion, margin positivity rates, time to first flatus (TtFF), time to first bowel movement (TtFBM), ileus and small bowel obstruction (SBO) rates, time to safe discharge (TtSD), postoperative hospital stay (PHS) and pain levels on a postoperative day (POD) 1 and 3. Perioperative complications were recorded using the Clavien-Dindo system. Results: Demographic and baseline clinical characteristics, LoP, EBL and margin positivity rates were similar between groups. No transfusions were recorded. Median (IQR) TtFF, TtFBM and TtSD were significantly longer in Group 1 vs Group 2 (4 (1) vs 2 (1), 7 (3) vs 6 (2) and 8.5 (5.75) vs 5.0 (1), respectively). PHS and rates of postoperative ileus and SBO were lower in Group 2, however not statistically significant. Severe pain was uncommon in both groups but moderate/severe pain was significantly higher in Group 1 (95.8% vs 48% on POD1 and 62.5% vs 16% on POD3). No significant intraoperative complications were recorded and ≥ Grade 3 postoperative complications at 30 and 90 days were similar. Conclusion: With limitations, Low-IAP RARC can be safely offered to RARC/ICUD patients and leads to faster bowel recovery, and shorter time to safe discharge compared to standard pneumoperitoneum.
- Open Access
- 29 January 2022
- Published by Wiley in BJU International
- Vol. 129 (4) , 460-462
A novel tattooing technique for ureteric strictures in robotic ureteroureterostomy: a non‐inferiority analysis
- 29 January 2022
- Published by Wiley in BJU International
- Vol. 129 (4) , 460-462
Open AccessA novel tattooing technique for ureteric strictures in robotic ureteroureterostomy: a non‐inferiority analysis
- 1 June 2021
- Published by Elsevier in European Urology
- Vol. 79, S458-S459
Surgical treatment of male Lichen Sclerosus-related urethral strictures disease: State of the art
- 1 June 2021
- Published by Elsevier in European Urology
- Vol. 79, S458-S459
Surgical treatment of male Lichen Sclerosus-related urethral strictures disease: State of the art
- Open Access
- 25 June 2020
- Published by Springer Nature in Nature Reviews Urology
- Vol. 17 (8) , 482
Author Correction: Introducing PIONEER: a project to harness big data in prostate cancer research
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
- 25 June 2020
- Published by Springer Nature in Nature Reviews Urology
- Vol. 17 (8) , 482
Open AccessAuthor Correction: Introducing PIONEER: a project to harness big data in prostate cancer research
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
- 14 January 2020
- Published by Springer Nature in World Journal of Urology
- Vol. 38 (11) , 2761-2770
Perioperative antithrombotic (antiplatelet and anticoagulant) therapy in urological practice: a critical assessment and summary of the clinical practice guidelines
Purpose The perioperative management of patients who are receiving antithrombotic (antiplatelet or anticoagulant) therapy and require urologic surgery is challenging due to the inherent risk for surgical bleeding and the need to minimize thromboembolic risk. The aim of this review is to assess the quality and consistency of clinical practice guidelines (CPGs) and clinical practice recommendations (CPRs) on this topic, and to summarize the evidence and associated strength of recommendations relating to perioperative antithrombotic management. Methods A pragmatic search of electronic databases and guidelines websites was performed to identify relevant CPGs/CPRs. The AGREE II (Appraisal of Guidelines for REsearch and Evaluation) instrument was used to assess the methodological quality and integrity of the CPGs. Results The CPGs provided by the European Association of Urology (EAU), the American College of Chest Physicians (ACCP) and the European Society of Cardiology/European Society of Anaesthesiology (ESC/ESA), and the CPRs provided by the International Consultation on Urological Disease (ICUD)/American Urologic Association (AUA) were retrieved and reviewed. The 3 CPGs were critically assessed using the AGREE II instrument. Inconsistent recommendations were provided based on the indication for antithrombotic medication, the antiplatelet/anticoagulant agent and the type of urological procedure. Based on the AGREE II tool for CPG assessment, the EAU CPGs scored higher (83.3 points) compared to the ESC/ESA (75 points) and ACCP CPG (66.7 points). Conclusion The perioperative management of antithrombotic therapy in urological patients is potentially challenging but inconsistent CPG of varying quality may create uncertainty as to best practices to minimize thromboembolic and bleeding risk.
- 14 January 2020
- Published by Springer Nature in World Journal of Urology
- Vol. 38 (11) , 2761-2770
Perioperative antithrombotic (antiplatelet and anticoagulant) therapy in urological practice: a critical assessment and summary of the clinical practice guidelines
Purpose The perioperative management of patients who are receiving antithrombotic (antiplatelet or anticoagulant) therapy and require urologic surgery is challenging due to the inherent risk for surgical bleeding and the need to minimize thromboembolic risk. The aim of this review is to assess the quality and consistency of clinical practice guidelines (CPGs) and clinical practice recommendations (CPRs) on this topic, and to summarize the evidence and associated strength of recommendations relating to perioperative antithrombotic management. Methods A pragmatic search of electronic databases and guidelines websites was performed to identify relevant CPGs/CPRs. The AGREE II (Appraisal of Guidelines for REsearch and Evaluation) instrument was used to assess the methodological quality and integrity of the CPGs. Results The CPGs provided by the European Association of Urology (EAU), the American College of Chest Physicians (ACCP) and the European Society of Cardiology/European Society of Anaesthesiology (ESC/ESA), and the CPRs provided by the International Consultation on Urological Disease (ICUD)/American Urologic Association (AUA) were retrieved and reviewed. The 3 CPGs were critically assessed using the AGREE II instrument. Inconsistent recommendations were provided based on the indication for antithrombotic medication, the antiplatelet/anticoagulant agent and the type of urological procedure. Based on the AGREE II tool for CPG assessment, the EAU CPGs scored higher (83.3 points) compared to the ESC/ESA (75 points) and ACCP CPG (66.7 points). Conclusion The perioperative management of antithrombotic therapy in urological patients is potentially challenging but inconsistent CPG of varying quality may create uncertainty as to best practices to minimize thromboembolic and bleeding risk.
- 27 March 2019
- Published by Springer Nature in International Journal Of Impotence Research
- Vol. 31 (6) , 380-391
What are the benefits and harms of testosterone therapy for male sexual dysfunction?—a systematic review
The role of Testosterone Therapy (TTh) in the management of male sexual dysfunction remains unclear. Objective of the authors was to systematically review the relevant literature assessing the benefits and harms of TTh in men with sexual dysfunction. EMBASE, MEDLINE, Cochrane Systematic Reviews—Cochrane Central Register of Controlled Trials (CENTRAL) (Cochrane HTA, DARE, HEED), Google Scholar, WHO international Clinical Trials Registry Platform Search Portal, CINAHL databases and clinicaltrial.gov were searched systematically in March 2015 and an updated search was performed in March 2016. Randomized and non-randomized comparative studies assessing the benefits and harms of TTh in hypogonadal, borderline eugonadal and eugonadal men suffering from sexual dysfunction were included. Risk of bias and confounding assessments were performed. A narrative synthesis was undertaken. Of the 6410 abstracts identified, 36 studies were judged to be eligible for inclusion, including 25 randomized clinical trials (RCTs) and 11 non-randomized comparative studies (NRCSs), recruiting a total of 4944 patients. RCTs were judged to have low or unclear risk of bias, while NRCSs had high risk of bias and thus, overall quality of evidence was judged to be at least unclear. Based on the evidence mainly provided by the RCTs included in this systematic review, TTh could be considered for men with low or low-normal testosterone levels and problems with their sexual desire, erectile function and satisfaction derived from intercourse and overall sexual life. The exact testosterone formulation, dosage and duration of treatment remain to be clarified, while the safety profile of TTh also remains unclear. TTh could be used with caution in hypogonadal and most probably borderline eugonadal men to manage disorders of sexual desire, erectile function and sexual satisfaction. The overall low-to-moderate evidence quality highlights the need for robust and adequately designed clinical trials.
- 27 March 2019
- Published by Springer Nature in International Journal Of Impotence Research
- Vol. 31 (6) , 380-391
What are the benefits and harms of testosterone therapy for male sexual dysfunction?—a systematic review
The role of Testosterone Therapy (TTh) in the management of male sexual dysfunction remains unclear. Objective of the authors was to systematically review the relevant literature assessing the benefits and harms of TTh in men with sexual dysfunction. EMBASE, MEDLINE, Cochrane Systematic Reviews—Cochrane Central Register of Controlled Trials (CENTRAL) (Cochrane HTA, DARE, HEED), Google Scholar, WHO international Clinical Trials Registry Platform Search Portal, CINAHL databases and clinicaltrial.gov were searched systematically in March 2015 and an updated search was performed in March 2016. Randomized and non-randomized comparative studies assessing the benefits and harms of TTh in hypogonadal, borderline eugonadal and eugonadal men suffering from sexual dysfunction were included. Risk of bias and confounding assessments were performed. A narrative synthesis was undertaken. Of the 6410 abstracts identified, 36 studies were judged to be eligible for inclusion, including 25 randomized clinical trials (RCTs) and 11 non-randomized comparative studies (NRCSs), recruiting a total of 4944 patients. RCTs were judged to have low or unclear risk of bias, while NRCSs had high risk of bias and thus, overall quality of evidence was judged to be at least unclear. Based on the evidence mainly provided by the RCTs included in this systematic review, TTh could be considered for men with low or low-normal testosterone levels and problems with their sexual desire, erectile function and satisfaction derived from intercourse and overall sexual life. The exact testosterone formulation, dosage and duration of treatment remain to be clarified, while the safety profile of TTh also remains unclear. TTh could be used with caution in hypogonadal and most probably borderline eugonadal men to manage disorders of sexual desire, erectile function and sexual satisfaction. The overall low-to-moderate evidence quality highlights the need for robust and adequately designed clinical trials.
- 15 March 2019
- Published by Elsevier in European Urology Supplements
- Vol. 18 (1) , e2136-e2137
The role of care pathways in urology: Vision of the European Association of Urology Guidelines Office
- 15 March 2019
- Published by Elsevier in European Urology Supplements
- Vol. 18 (1) , e2136-e2137
The role of care pathways in urology: Vision of the European Association of Urology Guidelines Office
- Open Access
- 31 July 2016
- Published by SAGE Publications in Therapeutic Advances in Medical Oncology
- Vol. 8 (5) , 331-338
Ultrasound-guided radiofrequency ablation for cT1a renal masses in poor surgical candidates: mid-term, single-center outcomes
Surgical management of small renal masses can be challenging in frail patients and thus modalities such as radiofrequency ablation (RFA) have emerged as valid alternative options. The aim of the current study was to present mid-term oncological and functional results on a series of patients with cT1a renal cell carcinomas (RCCs) who were unfit for surgery and underwent RFA using ultrasound guidance under local anesthesia. Data from patients fulfilling the study selection criteria were retrospectively collected. RENAL nephrometry score was used for tumor description. Parametric tests were used for data analysis and survival curves were estimated using the Kaplan–Meier method. Overall, 32 patients (mean±standard deviation age, 72.4 ± 7.6 years) with biopsy-proven RCCs (tumor size, 23.75 ± 10.44 mm and RENAL score, 5.28 ± 1.33) underwent 32 RFA sessions. Twenty-seven patients (84.4%) had low complexity masses and five patients had masses of intermediate complexity (15.6%) according to RENAL score categorization. Over a follow-up period of 22.1 ± 13.7 months, one case of primary treatment failure was recognized (primary technical success 97.0%), and overall, three patients were diagnosed with residual disease (primary technique effectiveness 90.6%). No major complications occurred during the postprocedure 90-day follow up, while no difference was found in serum creatinine and estimated glomerular filtration rate pre and post procedure. Patients with intermediate-complexity renal lesions had shorter time to recurrence in comparison to low-complexity masses (p = 0.002). All patients were alive at the time of study data analysis without diagnosed metastases. Percutaneous RFA of small RCCs using ultrasound-based guidance under local anesthesia can be an effective alternative method for managing patients who are unfit for surgery.
- 31 July 2016
- Published by SAGE Publications in Therapeutic Advances in Medical Oncology
- Vol. 8 (5) , 331-338
Open AccessUltrasound-guided radiofrequency ablation for cT1a renal masses in poor surgical candidates: mid-term, single-center outcomes
Surgical management of small renal masses can be challenging in frail patients and thus modalities such as radiofrequency ablation (RFA) have emerged as valid alternative options. The aim of the current study was to present mid-term oncological and functional results on a series of patients with cT1a renal cell carcinomas (RCCs) who were unfit for surgery and underwent RFA using ultrasound guidance under local anesthesia. Data from patients fulfilling the study selection criteria were retrospectively collected. RENAL nephrometry score was used for tumor description. Parametric tests were used for data analysis and survival curves were estimated using the Kaplan–Meier method. Overall, 32 patients (mean±standard deviation age, 72.4 ± 7.6 years) with biopsy-proven RCCs (tumor size, 23.75 ± 10.44 mm and RENAL score, 5.28 ± 1.33) underwent 32 RFA sessions. Twenty-seven patients (84.4%) had low complexity masses and five patients had masses of intermediate complexity (15.6%) according to RENAL score categorization. Over a follow-up period of 22.1 ± 13.7 months, one case of primary treatment failure was recognized (primary technical success 97.0%), and overall, three patients were diagnosed with residual disease (primary technique effectiveness 90.6%). No major complications occurred during the postprocedure 90-day follow up, while no difference was found in serum creatinine and estimated glomerular filtration rate pre and post procedure. Patients with intermediate-complexity renal lesions had shorter time to recurrence in comparison to low-complexity masses (p = 0.002). All patients were alive at the time of study data analysis without diagnosed metastases. Percutaneous RFA of small RCCs using ultrasound-based guidance under local anesthesia can be an effective alternative method for managing patients who are unfit for surgery.